Prevention of hepatocellular carcinoma complicating chronic hepatitis C. - Wikidata - awgldk - TriplyDB

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

http://www.wikidata.org/entity/Q37445121

about

Aminoadamantanes versus other antiviral drugs for chronic hepatitis C Aminoadamantanes for chronic hepatitis C Aminoadamantanes versus other antiviral drugs for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Aminoadamantanes for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks for patients with chronic hepatitis C virus genotype 1 infection having shown slow antiviral response Development and novel therapeutics in hepatocellular carcinoma: a review Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region Prevention of Hepatocellular Carcinoma Individualisation of antiviral therapy for chronic hepatitis C.Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.Effect of healthcare insurance policy on the quality of life of chronic hepatitis C patients receiving interferon α-2a plus ribavirin therapy.Hepatitis B- and hepatitis C-related hepatocellular carcinomas in the United States: similarities and differences Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.Malignancies after pediatric kidney transplantation: more than PTLD?Could ADC values be a promising diagnostic criterion for differentiating malignant and benign hepatic lesions in Asian populations: A meta-analysis.

P2860

Q24193940-B911CB54-3153-4834-9CF4-96C33C49B5CF Q24194770-22E867C8-D54D-4B08-B50A-0FDBED9D3D45 Q24194815-E2C5D089-E7DC-4365-A0F4-7EF7481C3AA6 Q24200534-86563FD9-F397-4505-8689-AA7E44128017 Q24201226-2054883D-A487-4F54-9D77-DBC2A206B157 Q24235606-5DE73032-9E0C-40DD-B229-66618B263AA6 Q26752854-035000AE-A464-4C6B-9DAE-DE9031D4B25E Q27026753-A9BA4F40-8965-4D23-A066-C9949E172637 Q28079576-F7935449-BEEE-4FC2-BE59-1ADA5C5BC167 Q33390478-0B1EF42B-3BF7-45D8-929E-6FF1F91D0B82 Q34347862-AEC11ADB-94EA-4220-8B70-E1B1DFF0F0C0 Q34348710-C06A8688-3B87-4614-B6FC-EB741AA43AEB Q36224751-1F269F58-0B45-41BD-B010-9CC2A8C547AF Q36454775-EF373AF2-81D4-418D-87A5-431086CCEAFD Q36792338-458E84B1-BBF0-4B12-8135-6573F840B3D9 Q38136078-D0FDDFA2-9271-48E0-AFF7-C3EAC8ED1C15 Q38141838-7BE3849D-9408-4241-B537-C050505D7A3D Q40449077-24D589AD-6238-4102-8192-D939AF45A1CD

P2860

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

http://www.wikidata.org/entity/Q37445121

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@en

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@nl

type

label

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@en

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@nl

prefLabel

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@en

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@nl

P1433

Q37445121-57EE9F50-7EFF-436B-8D29-E6A764B76DB1

P1476

Q37445121-94ABBB72-1E9F-4362-BC30-F68AAEEA0E15

P2093

Q37445121-7C090F70-4D7A-47AB-8853-42DA66D24A52

Q37445121-804D58CB-D5C5-4E7E-A660-74501E97301D

Q37445121-FCE38B73-48D5-4517-8562-206B36BC978B

P2860

Q37445121-090B57C7-185C-4194-8E45-9BF86752CE12

Q37445121-24B2B25E-849A-4213-9ED1-73F195D14D27

Q37445121-33AFCB4E-A673-401F-814F-0994AD11AB49

Q37445121-5D3BE9FC-3BEF-4AC2-9367-2678D89B27E3

Q37445121-CC90B85A-8918-4EBF-BAC2-0B35483E517C

Q37445121-D4CF715F-E0C5-4D74-876D-5BAEB7DBCFFD

P304

Q37445121-EEE0EE8B-71F8-4CF1-BE42-7432F5C0E314

P31

Q37445121-B3A463E2-592C-46D9-9888-02CBA708565D

P356

Q37445121-C909F7DC-EFC3-4B60-B379-35FDBC249BEA

P433

Q37445121-4792245F-6ACD-4F35-A4C6-79CA57CEF64E

P478

Q37445121-5C385D31-0F0B-4087-A477-152D77FAE8AB

P577

Q37445121-0812B2E6-F170-432A-B0A0-4787D7A18EB0

P698

Q37445121-F9786B9D-8C15-44A6-AC55-D48233321F32

P356

J.1440-1746.2009.05814.X

P1433

Journal of Gastroenterology and Hepatology

P1476

Prevention of hepatocellular carcinoma complicating chronic hepatitis C.

@en

P2093

Geoffrey C Farrell

http://www.w3.org/2001/XMLSchema#string

Jose D Sollano

http://www.w3.org/2001/XMLSchema#string

Yoshiyuki Ueno

http://www.w3.org/2001/XMLSchema#string

P2860

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.

Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection.

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

P304

531-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1440-1746.2009.05814.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19368633

http://www.w3.org/2001/XMLSchema#string